Qingdao FTZ pioneers growth in healthcare, life sciences industry

The Qingdao Area of the China (Shandong) Pilot Free Trade Zone (Qingdao FTZ) has become a center for healthcare and life sciences, with 69 active projects, five top-tier R&D institutions, and over 3,700 professionals.

Qingdao Guoxin Pharmaceutical is leading in pharmaceuticals and nearing a major milestone in oncology. "BG136, the world's first immune anti-tumor marine polysaccharide drug, will release its Phase II clinical report this March," said Chen Yangsheng, the company's vice president.

The drug is a result of teaming up with the Qingdao Marine Biomedical Research Institute and the Ocean University of China. Their success shows the FTZ's ability to leverage marine resources for global health solutions.

The Qingdao FTZ is also pushing the boundaries of genetic engineering. Qingdao KingAgroot CropScience, for instance, has over 100 patents for molecular breeding and more than 200 international patents, boosting the region's global biotech presence. 

The rapid growth of these enterprises is supported by a robust infrastructure. The FTZ has a 288,000-square-meter space for life science startups and big companies.

In 2025, the area got 18 new high-tech projects, speeding up the cluster effect. With top facilities and a steady flow of talent, the Qingdao FTZ will play a key role in the global life and health field.